ALK-Abelló A/S
ALK-B
Rank in Stocks
#2351
ALK-Abelló A/S is a global leader in allergy solutions, with operations... ALK-Abelló A/S is a global leader in allergy solutions, with operations spanning Europe, North America, and other international regions. The company offers a comprehensive portfolio of treatments for allergic rhinitis and allergic asthma, featuring key products such as GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX. ALK-Abelló specializes in allergy immunotherapy, providing options like injections, sublingual drops, and tablets to address a wide range of sensitivities, including those to grass, ragweed, house dust mites, Japanese cedar, various tree pollens, and certain foods. Furthermore, the company engages with consumers through a digital healthcare ecosystem, a platform designed to connect with allergy sufferers early in their journey, offering tools, e-commerce solutions, and guidance to support and streamline access to immunotherapy. ALK-Abelló also provides essential diagnostic allergy services, including skin prick and blood tests, alongside emergency treatments such as intramuscular adrenaline injections for severe, life-threatening allergic reactions like anaphylaxis. The company was established in 1923 and is based in Hørsholm, Denmark.
Share Price
$37.76
Market Cap
$8.38B
Change (1 day)
-0.08%
Change (1 year)
12.64%
Country
DK
Trade ALK-Abelló A/S (ALK-B)
Category
Healthcare
P/B ratio for ALK-Abelló A/S (ALK-B)
P/B ratio as of October 2026 TTM: 7.22
According to ALK-Abelló A/S latest financial reports and stock price the company's current price-to-book ratio (TTM) is 7.22. At the end of 2023 the company had a P/B ratio of 5.03.
P/B ratio history for ALK-Abelló A/S from 2004 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 7.22 | 10.28% |
| 2024 | 6.55 | 30.22% |
| 2023 | 5.03 | -5.24% |
| 2022 | 5.31 | -50.88% |
| 2021 | 10.81 | 24.92% |
| 2020 | 8.66 | 54.24% |
| 2019 | 5.61 | 62.86% |
| 2018 | 3.45 | 52.96% |
| 2017 | 2.25 | -28.29% |
| 2016 | 3.14 | -0.35% |
| 2015 | 3.15 | 17.99% |
| 2014 | 2.67 | 1.30% |
| 2013 | 2.64 | 57.44% |
| 2012 | 1.68 | 14.26% |
| 2011 | 1.47 | -7.18% |
| 2010 | 1.58 | -25.13% |
| 2009 | 2.11 | -24.41% |
| 2008 | 2.79 | -8.71% |
| 2007 | 3.06 | -17.15% |
| 2006 | 3.69 | 138.26% |
| 2005 | 1.55 | 0.00% |
| 2004 | 0.00 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 6.251 | -13.46% |
US
|
|
| 13.2547 | 83.50% |
US
|
|
| 4.208 | -41.74% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -14.41% |
NL
|
